Soleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Soleus Capital Management L.P. cut its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 52.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,500 shares of the company's stock after selling 49,500 shares during the period. Soleus Capital Management L.P. owned 0.06% of Viridian Therapeutics worth $872,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Loomis Sayles & Co. L P bought a new stake in shares of Viridian Therapeutics in the 4th quarter valued at $26,845,000. Price T Rowe Associates Inc. MD lifted its holdings in Viridian Therapeutics by 2,847.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock valued at $25,436,000 after buying an additional 1,281,799 shares during the period. Deep Track Capital LP lifted its holdings in Viridian Therapeutics by 20.6% in the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after buying an additional 771,796 shares during the period. FMR LLC boosted its position in Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after acquiring an additional 698,434 shares during the last quarter. Finally, Parkman Healthcare Partners LLC grew its holdings in Viridian Therapeutics by 155.9% during the 4th quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock worth $20,850,000 after acquiring an additional 662,634 shares during the period.

Viridian Therapeutics Stock Up 0.1%

Shares of NASDAQ VRDN traded up $0.01 during midday trading on Thursday, hitting $13.67. 568,146 shares of the stock traded hands, compared to its average volume of 1,194,027. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20. The business has a 50 day moving average price of $13.25 and a two-hundred day moving average price of $16.99. The company has a market cap of $1.12 billion, a PE ratio of -3.17 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. The business's revenue was up .0% on a year-over-year basis. On average, equities analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

VRDN has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday. HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Royal Bank of Canada cut their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group lowered their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, JMP Securities dropped their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $36.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.